U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Timothy Flanigan
  1. Science & Research (NCTR)

Timothy Flanigan Ph.D.

Research Psychologist — Division of Neurotoxicology

Tim Flanigan
Timothy Flanigan, Ph.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov  

Back to NCTR Principal Investigators page

 About  |  Publications 

Background

Dr. Timothy Flanigan received his Ph.D. in experimental psychology with a concentration in behavioral neuroscience in 2011. There he studied the role of genetics in anxiety- and depression-like behavior using mouse models. He went on to complete a postdoctoral fellowship in the Department of Neurology at the University of Tennessee Health Science Center. During that time, he conducted research using the 5xFAD mouse model of Alzheimer’s Disease and investigated the potential of manipulating brain gangliosides as a treatment. In 2015, Dr. Flanigan was recruited to NCTR as an ORISE postdoctoral fellow. He served on NCTR’s monograph team for nearly three years helping to create comprehensive reviews on over 50 compounds. He also conducted research examining the cognitive effects of chemotherapeutic agents, anesthesia, and developmental exposure to arsenic. In 2018, Dr. Flanigan became a staff fellow in the Division of Neurotoxicology.
 

Research Interests

Dr. Flanigan has a broad interest in behavioral neuroscience and neurotoxicology. He is particularly interested in cognitive and affective behaviors and modeling them in rodents. He is also interested in how genetics, development, and aging interact with drugs and toxicants to affect these behaviors.


Professional Societies/National and International Groups

Society for Neuroscience
Member 
2005 – Present

International Society for Behavioral Genetics
Member
2012 – Present

 

Selected Publications

Effects of Cyclophosphamide and/or Doxorubicin in a Murine Model of Postchemotherapy Cognitive Impairment.
Flanigan T.J., Anderson J.E., Elayan I., Allen A.R., and Ferguson S.A.
Toxicol Sci. 2018 Apr 1, 162(2):462-474. doi: 10.1093/toxsci/kfx267.

Abnormal Vibrissa-Related Behavior and Loss of Barrel Field Inhibitory Neurons in 5xFAD Transgenics.
Flanigan T.J., Xue Y., Kishan Rao S., Dhanushkodi A., and McDonald M.P.
Genes Brain Behav. 2014 Jun, 13(5):488-500. doi: 10.1111/gbb.12133. 

Effects of an Early Handling-Like Procedure and Individual Housing on Anxiety-Like Behavior in Adult C57BL/6J and DBA/2J Mice.
Flanigan T.J., and Cook M.N.
PLoS One. 2011 Apr 21, 6(4):e19058. doi: 10.1371/journal.pone.0019058.


 

Contact Information
Timothy Flanigan
(870) 543-7121
Expertise
Expertise
Approach
Domain
Technology & Discipline
Toxicology
Back to Top